Nektar Therapeutics (NKTR) Cash from Investing Activities Growth (1y) (2011 - 2026)
Nektar Therapeutics (NKTR) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7,936.68% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 26.37% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -157.08% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -89.24% |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -902.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -902.92% |
| Dec 31, 2025 | -99.38% |
| Sep 30, 2025 | -305.73% |
| Jun 30, 2025 | 192.16% |
| Mar 31, 2025 | 126.86% |
| Dec 31, 2024 | 246.40% |
| Sep 30, 2024 | -18.25% |
| Jun 30, 2024 | -32.53% |
| Mar 31, 2024 | -52.56% |
| Dec 31, 2023 | -56.56% |
| Sep 30, 2023 | -49.36% |
| Jun 30, 2023 | -70.09% |
| Mar 31, 2023 | -68.84% |
| Dec 31, 2022 | -66.71% |
| Sep 30, 2022 | 13,521.08% |
| Jun 30, 2022 | 15.35% |
| Mar 31, 2022 | 1,145.73% |
| Dec 31, 2021 | 29.61% |
| Sep 30, 2021 | -101.71% |
| Jun 30, 2021 | -53.55% |